news
Bovhyaluronidase azoximer significantly reduces exercise intolerance in patients with long-term pulmonary sequelae of COVID-19
Petrovax announced today the positive results from “Long-CoV-III-21”, a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19.
Pneumococcal vaccine reduces risk of death from pneumonia in patients with chronic diseases
Russian and Belarusian experts exchange experience in applying combined vaccination against influenza and pneumococcal infection
Full preparedness for influenza season
Scientific studies confirm Uronext’s benefits for treating urinary tract infections
Petrovax changes packaging design for Polyoxidonium
Experts evaluate role of Polyoxidonium in rhinosinusitis
Twenty years to make a diagnosis: how specialists identify and treat patients with Fabry disease in Russia?
Leading pulmonologists talk about latest advances in treatment options for post-COVID pulmonary fibrosis
